47 citations
,
January 2013 in “International Journal of Cosmetic Science”
This review explores genetic and lifestyle factors influencing hair diversity and reports no new findings, calling attention to the potential for future discoveries in genetic and epigenetic research.
41 citations
,
October 2000 in “Dermatologic clinics”
This paper reviews hair structure and damage from grooming and cosmetic exposure but reports no new clinical findings; it suggests collaboration between dermatologists and cosmetic chemists to improve hair care products.
11 citations
,
February 2002 in “International Journal of Cosmetic Science”
This review describes recent findings in hairbiology, highlighting the diverse molecular signals that regulate hair growth and pigmentation, but presents no new experimental results.
Will I lose my hair if I stop using RU58841? (Spoiler: I might.)There is no published human trial of stopping RU58841; community members commonly report shedding within weeks to months, and androgen biology suggests miniaturization would resume once the topical anti-androgen is withdrawn.
Protein that blocks activin, a growth-regulating signal
Are there any clinical studies supporting follistatin as a hair loss treatment?There is no controlled human trial showing follistatin treats hair loss; the published work is mouse and laboratory biology on the activin/follistatin signalling system, plus one small 2011 phase 1 injection study of a combination product, so follistatin remains experimental and unapproved.
Hair transplant success largely depends on individual biology, with many patients needing multiple procedures to achieve satisfactory density. Even top surgeons can't guarantee results, and many people use additional treatments like Minoxidil and Finasteride.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
A 42-year-old male has reached a plateau in hair regrowth after 8 months using Dutasteride, Minoxidil, a dermaroller, and Ketoconazole. Suggestions include continuing treatment, considering a hair transplant, and improving nutrition.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.